Business Context and Reporting Period
This Form 8-K is filed by Ekso Bionics Holdings, Inc. (not Chronoscale Corp) on January 13, 2025. The report provides preliminary, unaudited financial results for the fourth quarter ended December 31, 2024. The company is incorporated in Nevada and trades on the Nasdaq Capital Market under the symbol EKSO.
Key Financial Metrics
| Metric | Q4 2024 (Estimated) | Q4 2023 (Actual) |
|---|---|---|
| Total Revenue | $5.0 million to $5.1 million | $4.8 million |
| Cash Balance (as of Dec 31) | $6.5 million | $8.6 million |
| Net Cash Used in Operations | $1.5 million | $1.6 million |
| Profit/Loss | Not provided | Not provided |
| Debt | Not provided | Not provided |
Material Changes vs. Prior Period
- Revenue Growth: Q4 2024 revenue is projected to be a company record, representing an increase from $4.8 million in Q4 2023.
- Cash Position: Cash reserves decreased by $2.1 million year-over-year, dropping from $8.6 million to $6.5 million.
- Operating Cash Flow: Net cash used in operations improved slightly, decreasing from $1.6 million in Q4 2023 to an estimated $1.5 million in Q4 2024.
Guidance, Outlook, and Risks
The filing contains no specific forward-looking guidance beyond the preliminary Q4 2024 estimates. Management notes that the financial data is unaudited and subject to adjustment during the final quarter-end closing process. The report includes standard forward-looking statement disclaimers, warning that actual results may differ materially due to risks including the finalization of financial statements and changes in facts or circumstances prior to the filing of the Form 10-K.
Investor Verification Checklist
- Verify the final audited Q4 2024 revenue figure against the preliminary range of $5.0M–$5.1M.
- Confirm the final cash balance and any material adjustments to the $6.5 million estimate upon the release of the Form 10-K.
- Review the full text of the press release (Exhibit 99.1) for additional operational details not summarized in the 8-K.
- Monitor the upcoming Form 10-K filing for the full year 2024 results and updated liquidity analysis.